(PDF/87.96 KB)

This study was originally designed to assess the long-term safety of the capsules, but the company later extended its aim to include the assessment of the benefits and risks of the transdermal patch in the treatment of dementia associated with Parkinson's disease. (PDF/63.2 KB) (PDF/134.74 KB) (PDF/87.96 KB) (PDF/86.33 KB) (PDF/133.76 KB) (PDF/88.68 KB)

(PDF/60.88 KB) (PDF/137.04 KB) (PDF/82.39 KB) (PDF/120.92 KB) (PDF/107.64 KB) (PDF/135.03 KB) (PDF/135.03 KB) (PDF/60.39 KB) (PDF/86.33 KB)

The United Kingdom (UK) withdrew from the European Union (EU) on 31 January 2020 and is no longer an EU Member State. (PDF/135.54 KB) (PDF/62.53 KB) (PDF/88.58 KB) After the CHMP had assessed the company's responses to the questions, there were still some unresolved issues.Based on the review of the data and the company's response to the CHMP lists of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that the transdermal patch could not have been approved for the treatment of mild to moderately severe dementia associated with Parkinson's disease.The Committee was concerned that the new study was not sufficient to conclude on the effectiveness of the patch in patients with dementia associated with Parkinson's disease. (PDF/146.09 KB) If the site still contains content that does not yet reflect the withdrawal of the UK from the EU, this is unintentional and will be addressed. (PDF/148.38 KB) (PDF/136.64 KB) (PDF/115.2 KB)

(PDF/87.96 KB) About half of the patients took the capsule, and half were treated with the patch, for 76 weeks. (PDF/132.34 KB)

(PDF/132.34 KB) (PDF/61.87 KB) (PDF/60.88 KB) (PDF/135.28 KB) The company also presented a 'pharmacokinetic' analysis of the way rivastigmine from the patch is handled in the body when given to patients with dementia associated with Parkinson's disease, compared with what is seen in patients with Alzheimer's dementia.The application was withdrawn after 'day 90'. (PDF/136.46 KB) They are available as capsules, an oral solution and transdermal patches (patches that deliver the medicine across the skin). (PDF/132.34 KB) (PDF/60.88 KB) The company had presented pharmacokinetic data showing that, when using the patch, rivastigmine levels in patients with Parkinson's disease were similar to the levels seen in patients with Alzheimer's, but the CHMP noted that the dementia in the two diseases was different and could respond differently to treatment. (PDF/137.64 KB)

(PDF/63.2 KB) Any drug that has both toxicity and a “reward” effect, such as providing pain relief, has a capacity to become addictive.

The only thing you may experience while stopping the paracetamol is a return of pain or headaches.